media – Page 42 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Pioneering Helicobacter pylori new drug faces commercialization challenge

Recently, Dannuo Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as Dannuo Pharmaceutical) submitted a prospectus to the Hong Kong Stock Exchange, intending to list on the main board, which immediately attracted high attention from the capital market. Dano Pharmaceuticals’ new Helicobacter pylori drug, Leflunomide (TNP-2198), is experiencing a thrilling leap before commercialization – this world’s first differentiated antibiotic, which has advanced to the Phase III clinical endpoint, is regarded as the “hope of the whole village” by the company, but also carries the triple test of solving the drug resistance dilemma, overcoming medical insurance barriers, and increasing sales volume. As a potential solution for 44% of the infected population in China, the clinical value of levofloxacin and the 775 million yuan commercial betting agreement ignite capital imagination; But Dano Pharmaceuticals’ 530% debt ratio and cash flow crisis have made the market closely monitor every move in its August NDA submission ...
- Source: drugdu
- 95
- August 19, 2025
Asia Pharma Expo

Organiser: Nexzen Solutions Pvt. Ltd. Time：February 12 – February 14, 2026 address：Plot# 66, Block#C, Umme Kulsum Road, Bashundhara R/A, Dhaka-1229, Bangladesh Exhibition hall：International Convention City, Bashundhara Dhaka Product range: Pharmaceutical processing machinery (for tablets/capsules/liquids/injectables/ointments/dry syrups) Packaging machinery and equipment, packaging materials, API consumables, raw material drug additives, auxiliary materials, finished pharmaceutical products, and formulation laboratory reagents Glass products and equipment for analysis, R&D equipment, biotechnology instruments, and environmental control equipment Service utility products, one-stop service contractors, and project consulting services About Asia Pharma Expo： The Asia Pharma Expo in Dhaka, Bangladesh, is the most large-scale, influential, and the only internationally standardized pharmaceutical raw materials and equipment exhibition in Bangladesh. Strongly supported by the Bangladesh Pharmaceutical Industry Association, it serves as a vital platform for pharmaceutical information exchange in Bangladesh and its surrounding regions.
- Source: drugdu
- 249
- August 19, 2025
Doctors Seek Best Way to Treat Newly Discovered Genetic Disorder

By Carole Tanzer Miller HealthDay ReporterSATURDAY, Aug. 16, 2025 (HealthDay News) — Most folks probably think of gene mutations as something people are born with, but genes can also change later in life, sometimes making people sick. Scientists recently discovered a new disease that starts just that way in midlife. Called VEXAS, it’s marked by repeated attacks of inflammation caused by an immune system that goes rogue and attacks its own cells. “Part of normal aging is that all our cells develop mutations,” Dr. David Beck, a New York University geneticist who was part of the team that discovered VEXAS, told NIH News in Health. “It’s just normal wear and tear on our cells as we get older.” The type of mutation that causes VEXAS — known as an acquired mutation — is not passed on from parent to child. Acquired mutations develop, instead, over a lifetime, and exposure to ...
- Source: drugdu
- 76
- August 18, 2025
Amino acid metabolism shapes the tumor immune microenvironment and therapy response

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients, are now known to steer cell fate, immune suppression, and resistance to immunotherapy. Tumors often win this battle by monopolizing amino acids, crippling the metabolism of nearby T cells and macrophages. Recent advances have illuminated how this biochemical imbalance hinders immune surveillance and fosters tumor progression. Due to these challenges, there is a growing urgency to explore how amino acid dynamics influence cancer immunity and identify new therapeutic targets within this hidden battleground. In a new review (DOI: 10.20892/j.issn.2095-3941.2025.0115) published in Cancer Biology & Medicine, scientists from Tongji University Cancer Center explored how amino acid metabolism governs the intricate dialogue between cancer cells and immune defenses. The paper charts a comprehensive map of how amino acid sensing, transport, ...
- Source: drugdu
- 91
- August 18, 2025
The company is not involved in the vaccine business

Everyday AI Newsflash: An investor asked on the investor interaction platform: Has the company participated in the research and development of an AIDS vaccine? Does the company have this technology? Tiantan Biological (600161.SH) stated on the investor interaction platform on August 15 that the company is not involved in the vaccine business. The company’s main business is the research and development, production and sales of blood products, and it is in the blood products industry. At present, the company has launched three major categories of products, namely human albumin, human immunoglobulin and human coagulation factor, as well as recombinant coagulation factor products. https://finance.eastmoney.com/a/202508153485469676.html
- Source: drugdu
- 69
- August 18, 2025
Shingrix is superior to HZ/su vaccine in head-to-head comparison

On August 18th, Green Bamboo Biology-B (02480) announced that a head-to-head comparative study of its core product LZ901 and the recombinant glycoprotein E(gE) subunit vaccine HZ/su vaccine (Shingrix®) was conducted, and positive immunogenicity and safety data were obtained. This study recruited 301 healthy adults aged 50 and above. The results showed that LZ901 was superior to the HZ/su vaccine in both cellular immunogenicity and safety. In terms of specific immunogenicity results, LZ901 did not perform worse than the HZ/su vaccine in CD4+ and CD8+T cell immune responses. The proportion of gE specific CD4+T cell responders was 83.0%, while that of the HZ/su vaccine was 58.1%. The proportion of gE specific CD8+T cell responders was 46.8%, and that of HZ/su vaccine was 8.8%. In terms of safety, the adverse reaction rate of LZ901 was 41.1%, significantly lower than 87.9% of the HZ/su vaccine, and most of the reported reactions were mild ...
- Source: drugdu
- 78
- August 18, 2025
Soaring 1515%! The “champion of growth rate” among innovative drugs has made its debut

Amid the ever-changing capital market, the increase in the share price of Beihai Kangcheng is undoubtedly a remarkable and phenomenon-level event. Starting from a low of HK $0.13 at the beginning of this year, the share price of Cansino Biologics has been surging. As of the close of trading on August 13th, it has soared to HK $2.1, achieving an astonishing growth of over 15 times compared to the beginning of the year, with an increase of as high as 1,515%. This astonishing increase has become a hot topic of discussion in the capital market. In the current highly competitive pharmaceutical industry and with rapidly changing policy environments, why has the share price of Cansino Biologics been able to soar and become a favorite of the capital market? Good news keeps coming The share price of Beihai Kangcheng has soared, mainly due to the recent dual positive factors. On August ...
- Source: drugdu
- 82
- August 18, 2025
Zhonghui Bio-B recombinant RSV vaccine approved by FDA and CDE

On August 17, Zhonghui Bio-B (02627) announced that its independently developed recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvanted) had received approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration and the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This vaccine was developed to target respiratory syncytial virus (RSV), a significant cause of respiratory infections in infants, the elderly, and immunocompromised individuals. According to the announcement, the company’s vaccine demonstrated higher pre-F protein expression levels (approximately 1,000 to 1,500 mg/L) in preclinical studies than the marketed recombinant RSV vaccine (approximately 600 to 800 mg/L for the marketed product). Furthermore, after 14 days at 40°C, the company’s pre-F protein activity remained above 95%, while the marketed product’s activity decreased to approximately 50%. This demonstrates that the company’s vaccine is more stable and immunogenic than similar products. While the company ...
- Source: drugdu
- 60
- August 18, 2025
【EXPERT Q&A】How can one query the natural medicines approved in the past decade and their sources through the FDA drug approval database?

Drugdu.com expert’s response: To query FDA-approved natural drugs and their sources over the past decade through the FDA drug approval databases, the following systematic workflow can be followed, integrating FDA official resources with natural product classification logic for efficient retrieval: I. Define Search Objectives and Natural Drug Categories Natural drugs typically refer to active ingredients directly derived from plants, microorganisms, marine organisms, or minerals, as well as their structurally modified derivatives. Key focus areas include: Plant-derived: Examples include paclitaxel (from Pacific yew) and artemisinin (from sweet wormwood). Microorganism-derived: Examples include erythromycin (from actinomycetes) and cyclosporine (from fungi). Marine-derived: Examples include trabectedin (from sea squirts) and eribulin (from sponges). II. Leverage FDA Core Databases for Screening Drugs@FDA Database Steps: Access the database and select “Advanced Search”. Set the “Approval Date Range” to the past decade (e.g., January 1, 2015, to December 31, 2025). Enter natural product-related keywords in the “Active Ingredient” ...
- Source: drugdu
- 147
- August 18, 2025
Quanguo Fund conducts research on Shenlian Biotechnology, and Shizhiyuan is conducting a phase II clinical trial of chronic spontaneous urticaria in China

According to the disclosed institutional research information, Quanguo Fund conducted research on listed company Shenlian Biotechnology from August 6, 2025 to August 8, 2025. Attached research content: 1、 An introduction was given on the recent business situation of the company, the research and development progress of new products such as multi valent vaccines, the company’s layout and positioning in the field of human biological products, and the future coordinated development strategy of animal protection and human drug use. 2、 Main communication Q&A Quan Guo Fund Q1. Please introduce the basic situation of Yangzhou Shizhiyuan Biotechnology Co., Ltd. Answer: Yangzhou Shizhiyuan Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise established in October 2020. At the beginning of its establishment, it was an important biopharmaceutical development base set up by the United Biomedical, Inc. (UBI) group in mainland China, focusing on innovative drug development, clinical approval, project management, and promoting clinical trial ...
- Source: drugdu
- 120
- August 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.